FoxA1 is a key mediator of hormonal response in breast and prostate cancer

Frontiers in Endocrinology

Volumn 3, Issue MAY, 2012, Pages

  Robinson, Jessica L L ^a,b   Carroll, Jason S ^a,b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Breast cancer; ChIP Seq; Chromatin; Drug response; FoxA1; Prostate cancer; Transcription

Indexed keywords

EID: 84874507326     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00068     Document Type: Short Survey

References (42)

1. Badve, S., Turbin, D., Thorat, M. A., Morimiya, A., Nielsen, T. O., Perou, C. M., Dunn, S., Huntsman, D. G., and Nakshatri, H. (2007). FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clin. Cancer Res. 13, 4415-4421.
2. Bernardo, G. M., and Keri, R. A. (2012). FOXA1: a transcription factor with parallel functions in development and cancer. Biosci. Rep. 32, 113-130.
3. Bernardo, G. M., Lozada, K. L., Miedler, J. D., Harburg, G., Hewitt, S. C., Mosley, J. D., Godwin, A. K., Korach, K. S., Visvader, J. E., Kaestner, K. H., AbdulKarim, F. W., Montano, M. M., and Keri, R. A. (2010). FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis.Development 137, 2045-2054.
4. Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., and Tilley, W. D. (1995). Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 52, 459-467.
5. Brown, R. S. D., Edwards, J., Dogan, A., Payne, H., Harland, S. J., Bartlett, J. M. S., and Masters, J. R. W. (2002). Amplification of the androgen receptor gene in bone metastases from hormonerefractory prostate cancer. J. Pathol. 198, 237-244.
6. Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., Fox, E. A., Silver, P. A., and Brown, M. (2005). Chromosomewidemapping of estrogen receptor binding reveals longrange regulation requiring the forkhead protein FoxA1. Cell 122, 33-43.
7. Carroll, J. S., Meyer, C. A., Song, J., Li, W., Geistlinger, T. R., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G. F., Wang, Q., Bekiranov, S., Sementchenko, V., Fox, E. A., Silver, P. A., Gingeras, T. R., Liu, X. S., and Brown, M. (2006). Genomewide analysis of estrogen receptor binding sites. Nat. Genet. 38, 1289-1297.
8. Clark, K. L., Halay, E. D., Lai, E., and Burley, S. K. (1993). Cocrystal structure of the HNF3/fork head DNArecognition motif resembles histone H5. Nature 364, 412-420.
9. Costa, R. H., Grayson, D. R., and Darnell, J. E. (1989). Multiple hepatocyteenriched nuclear factors function in the regulation of transthyretin and alpha 1antitrypsin genes. Mol. Cell. Biol. 9, 1415-1425.
10. Doane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C., and Gerald, W. L. (2006). An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25, 3994-4008.
11. Edwards, J., Krishna, N. S., Grigor, K. M., and Bartlett, J. M. S. (2003). Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89, 552-556.
12. Eeckhoute, J., Lupien, M., Meyer, C. A., Verzi, M. P., Shivdasani, R. A., Liu, X. S., and Brown, M. (2009). Celltype selective chromatin remodeling defines the active subset of FOXA1bound enhancers. Genome Res. 19, 372-380.
13. Farmer, P., Bonnefoi, H., Becette, V., TubianaHulin, M., Fumoleau, P., Larsimont, D., Macgrogan, G., Bergh, J., Cameron, D., Goldstein, D., Duss, S., Nicoulaz, A.L., Brisken, C., Fiche, M., Delorenzi, M., and Iggo, R. (2005). Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24, 4660-4671.
14. Ford, O. H. III, Gregory, C. W., Kim, D., Smitherman, A. B., and Mohler, J. L. (2003). Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J. Urol. 170, 1817-1821.
15. Gao, N., Ishii, K., Mirosevich, J., Kuwajima, S., Oppenheimer, S. R., Roberts,R. L., Jiang,M.,Yu, X.,Shappell, S. B., Caprioli, R. M., Stoffel, M., Hayward, S. W., and Matusik, R. J. (2005). Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 132, 3431-3443.
16. Gao, N., Zhang, J., Rao, M. A., Case, T. C., Mirosevich, J., Wang, Y., Jin, R., Gupta, A., Rennie, P. S., and Matusik, R. J. (2003). The role of hepatocyte nuclear factor3 alpha (forkhead box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17, 1484-1507.
17. Gerhardt, J., Montani, M., Wild, P., Beer, M., Huber, F., Hermanns, T., Müntener, M., and Kristiansen,G. (2012). FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castrateresistant prostate cancer. Am. J. Pathol. 180, 848-861.
18. Hannenhalli, S., and Kaestner, K. H. (2009). The evolution of Fox genes and their role in development and disease.Nat. Rev. Genet.10, 233-240.
19. Hegde, N. S., Sanders, D. A., Rodriguez, R., and Balasubramanian, S. (2011). The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat. Chem. 3, 829-829.
20. Hisamatsu, Y., Tokunaga, E., Yamashita, N., Akiyoshi, S., Okada, S., Nakashima, Y., Aishima, S., Morita, M., Kakeji, Y., and Maehara, Y. (2011). Impact of FoxA1 expression on the prognosis of patients with hormone receptorpositive breast cancer. Ann. Surg. Oncol. 19, 1145-1152.
21. Hurtado, A., Holmes, K. A., RossInnes, C. S., Schmidt, D., and Carroll, J. S. (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33.
22. Jain, R. K., Mehta, R. J., Nakshatri, H., Idrees, M. T., and Badve, S. S. (2011). Highlevel expression of forkheadbox protein A1 in metastatic prostate cancer. Histopathology 58, 766-772.
23. Jia, L., Berman, B. P., Jariwala, U., Yan, X., Cogan, J. P., Walters, A., Chen, T., Buchanan, G., Frenkel, B., and Coetzee, G. A. (2008). Genomic androgen receptoroccupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 3, e3645. doi:10.1371/journal.pone.0003645
24. Joseph, R., Orlov, Y. L., Huss, M., Sun, W., Li Kong, S., Ukil, L., Fu Pan,Y., Li, G., Lim, M., Thomsen, J. S., Ruan, Y, arke, N. D., Prabhakar, S., Cheung, E., and Liu, E. T. (2010). Integrative model of genomic factors for determining binding site selection by estrogen receptor[alpha]. Mol. Syst. Biol. 6, 456.
25. Kong,S. L., Li,G., Loh, S. L.,Sung,W.K., and Liu, E. T. (2011). Cellular reprogramming by the conjoint action of ER[alpha], FOXA1, and GATA3 to a ligandinducible growth state. Mol. Syst. Biol. 7, 526.
26. Laganiere, J. E., Deblois, G. V., Lefebvre, C. L., Bataille, A. R., Robert, F. O., and Giguere, V. (2005). Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U.S.A. 102, 11651-11656.
27. Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., and Brown, M. (2008). FoxA1 translates epigenetic signatures into enhancerdriven lineagespecific transcription. Cell 132, 958-970.
28. Mehta, R., Jain, R., Leung, S., Choo, J., Nielsen, T., Huntsman, D., Nakshatri, H., and Badve, S. (2012). FOXA1 is an independent prognostic marker for ERpositive breast cancer. Breast Cancer Res. Treat. 131, 881-890.
29. Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., Rimm, D. L., Liu, S. X., and Brown, M. (2011). Targeting androgen receptor in estrogen receptornegative breast cancer. Cancer Cell 20, 119-131.
30. Robinson, J. L. L., Macarthur, S., RossInnes, C. S., Tilley, W. D., Neal, D. E., Mills, I. G., and Carroll, J. S. (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 30, 3019-3027.
31. Robyr, D., Gegonne, A., Wolffe, A. P., and Wahli, W. (2000). Determinants of vitellogenin B1 promoter architecture. J. Biol. Chem. 275, 28291-28300.
32. RossInnes, C. S., Stark, R., Holmes, K. A., Schmidt, D., Spyrou, C., Russell, R., Massie, C. E., Vowler, S. L., Eldridge, M., and Carroll, J. S. (2010). Cooperative interaction between retinoic acid receptorα and estrogen receptor in breast cancer. Genes Dev. 24, 171-182.
33. RossInnes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., Brown, G. D., Gojis, O., Ellis, I. O., Green, A. R., Ali, S., Chin, S.F., Palmieri, C., Caldas, C., and Carroll, J. S. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393.
34. Sahu, B., Laakso, M., Ovaska, K., Mirtti, T., Lundin, J., Rannikko, A., Sankila, A., Turunen, J.P., Lundin, M., Konsti, J., Vesterinen, T., Nordling, S., Kallioniemi, O., Hautaniemi, S., and Janne, O. A. (2011). Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 30, 3962-3976.
35. Sérandour, A. L. A., Avner, S. P., Percevault, F. D. R., Demay, F., Bizot, M., LucchettiMiganeh, C. L., BarloyHubler, F. D. R., Brown, M., Lupien, M., Metivier, R. L., Salbert, G., and Eeckhoute, J. R. M. (2011). Epigenetic switch involved in activation of pioneer factor FOXA1dependent enhancers. Genome Res. 21, 555-565.
36. Tan, P. Y., Chang, C. W., Chng, K. R., Wansa, K. D. S. A., Sung, W.K., and Cheung, E. (2012). Integration of regulatory networks by NKX31 promotes androgendependent prostate cancer survival. Mol. Cell. Biol. 32, 399-414.
37. Teschendorff, A., Miremadi, A., Pinder, S., Ellis, I., and Caldas, C. (2007). An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 8, R157.
38. Wang, D., GarciaBassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu, W., Kaikkonen, M. U., Ohgi, K. A., Glass, C. K., Rosenfeld, M. G., and Fu, X.D. (2011). Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390-394.
39. Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Janne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., and Brown, M. (2007). A hierarchical network of transcription factors governs androgen receptordependent prostate cancer growth. Mol. Cell 27, 380-392.
40. Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., Wu, T., Regan, M. M., Meyer, C. A., Carroll, J. S., Manrai, A. K., Janne, O. A., Balk, S. P., Mehra, R., Han, B., Chinnaiyan, A. M., Rubin, M. A., True, L., Fiorentino, M., Fiore, C., Loda, M., Kantoff, P. W., Liu, X. S., and Brown, M. (2009). Androgen receptor regulates a distinct transcription program in androgenindependent prostate cancer. Cell 138, 245-256.
41. Zaret, K. S., and Carroll, J. S. (2011). Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 25, 2227-2241.
42. Zhang, C., Wang, L., Wu, D., Chen, H., Chen, Z., ThomasAhner, J. M., Zynger, D. L., Eeckhoute, J., Yu, J., Luo, J., Brown, M., Clinton, S. K., Nephew, K. P., Huang, T. H.M., Li, W., and Wang, Q. (2011). Definition of a FoxA1 cistrome that is crucial for G1 to Sphase cellcycle transit in castrationresistant prostate cancer. Cancer Res. 71, 6738-6748.